98%
921
2 minutes
20
Background: Rotational thrombelastometry (ROTEM) has been used to evaluate the coagulation state, predict transfusion, and optimize hemostatic management in trauma patients. However, there were limited studies on whether the prediction value could be improved by adding the ROTEM parameter to the prediction model for in-hospital mortality and massive transfusion (MT) in trauma patients.
Objective: This study assessed whether ROTEM data could improve the MT prediction model.
Method: This was a single-center, retrospective study. Patients who presented to the trauma center and underwent ROTEM between 2016 and 2020 were included. The primary and secondary outcomes were massive transfusions and in-hospital mortality, respectively. We constructed two models using multivariate logistic regression with backward conditional stepwise elimination (Model 1: without the ROTEM parameter and Model 2: with the ROTEM parameter). The area under the receiver operating characteristic curve (AUROC) was calculated to assess the predictive ability of the models.
Result: In total, 969 patients were included; 196 (20.2%) received MT. The in-hospital mortality rate was 14.1%. For MT, the AUROC was 0.854 (95% confidence interval [CI], 0.825-0.883) and 0.860 (95% CI, 0.832-0.888) for Model 1 and 2, respectively. For in-hospital mortality, the AUROC was 0.886 (95% CI, 0.857-0.915) and 0.889 (95% CI, 0.861-0.918) for models 1 and 2, respectively. The AUROC values for models 1 and 2 were not statistically different for either MT or in-hospital mortality.
Conclusion: We found that the addition of the ROTEM parameter did not significantly improve the predictive power of MT and in-hospital mortality in trauma patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588372 | PMC |
http://dx.doi.org/10.1155/2022/7219812 | DOI Listing |
Acta Biomater
August 2025
Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Germany. Electronic address:
Background: Reliable in-vitro thrombogenicity testing of medical devices requires large blood volumes, which cannot be obtained from humans. Slaughterhouse blood is an ethically acceptable, cost-effective alternative. While porcine blood is already used in hemolysis testing, its use for thrombogenicity testing remains limited regarding its comparability to human blood.
View Article and Find Full Text PDFJ Thromb Haemost
August 2025
Northwell, New Hyde Park, NY, Cohen Children's Medical Center, Division of Pediatric Hematology, Oncology and Stem Cell Transplant, USA ,. Electronic address:
Introduction: Rotational Thromboelastometry (ROTEM) is a whole blood viscoelastic analyzer providing a global assessment of coagulation. Reference Intervals (RIs) for ROTEM are limited in pediatrics, often not accounting for race. Moreover, discrete RIs may be misleading.
View Article and Find Full Text PDFRes Pract Thromb Haemost
July 2025
Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Background: Low doses of recombinant activated factor (F)VII (rFVIIa), used to manage bleeding in patients with severe FXI deficiency, have been proposed to bypass effects of the FXI/FXIa inhibitor abelacimab.
Objectives: To test whether low concentrations of rFVIIa could abolish changes in coagulation parameters induced by abelacimab as measured by rotational thromboelastometry.
Methods: Whole blood specimens obtained in citrated tubes from 6 healthy donors were incubated with 15 and 30 μg/mL of abelacimab or vehicle for 10 minutes at 37 °C.
Transfusion
July 2025
Department of Emergency Medicine, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.
Background: Rotational thromboelastometry (ROTEM) is a blood test that measures hemostatic parameters to guide hemostatic therapy. ROTEM outputs can be cognitively challenging to interpret, which may limit adherence in trauma care. Our objective was to assess hemostatic therapy administration adherence to local ROTEM recommendations.
View Article and Find Full Text PDFThromb J
July 2025
Department of Hemostasis Disorders, Medical University of Lodz, Pabianicka 62, Łódź, 93-513, Poland.
Background: Antiphospholipid antibodies (aPLs) are detected in 1-5% of the general population. They include lupus anticoagulant (LAC), anticardiolipin antibodies (aCL) and anti-β2-glycoprotein I antibodies (aβ2GPI). APL increases thrombotic risk, but the pathogenesis of this effect is not fully understood.
View Article and Find Full Text PDF